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Abstract
Objective: Interferon (IFN) signaling plays a crucial role in autoimmunity. Genetic variation in interferon regulatory
factor 5 (IRF5), a major regulator of the type I interferon induction, has been associated with risk of developing
several autoimmune diseases. In the current study we aimed to evaluate whether three sets of correlated IRF5
genetic variants, independently associated with SLE and with different functional roles, are involved in uveitis
susceptibility and its clinical subphenotypes.
Methods: Three IRF5 polymorphisms, rs2004640, rs2070197 and rs10954213, representative of each group, were
genotyped using TaqMan® allelic discrimination assays in a total of 263 non-anterior uveitis patients and 724 healthy
controls of Spanish origin.
Results: A clear association between two of the three analyzed genetic variants, rs2004640 and rs10954213, and
the absence of macular edema was observed in the case/control analysis (PFDR=5.07E-03, OR=1.48, CI
95%=1.14-1.92 and PFDR=3.37E-03, OR=1.54, CI 95%=1.19-2.01, respectively). Consistently, the subphenotype
analysis accordingly with the presence/absence of this clinical condition also reached statistical significance
(rs2004640: P=0.037, OR=0.69, CI 95%=0.48-0.98; rs10954213: P=0.030, OR=0.67, CI 95%=0.47-0.96), thus
suggesting that both IRF5 genetic variants are specifically associated with the lack of macular edema in uveitis
patients.
Conclusion: Our results clearly showed for the first time that two functional genetic variants of IRF5 may play a role
in the development of macular edema in non-anterior uveitis patients. Identifying genetic markers for macular edema
could lead to the possibility of developing novel treatments or preventive therapies.
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Introduction
Uveitis is a general term used to describe a diverse group of
clinical entities with a variety of etiologies. It is one of the
leading causes of blindness worldwide accounting for about
10% of the severe visual handicap [1,2]. Uveitis patients are
frequently classified according to the anatomical location of the
inflammation into anterior uveitis (AU), the most common form,
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intermediate uveitis (IU), posterior uveitis (PU) and panuveitis
or also called diffuse uveitis (PAN) [3].
Non-infectious uveitis is believed to have an autoimmune
component [4,5]. Studies in human and animal models have
suggested that autoimmune uveitis presents a complex
inheritance pattern with multiple genetic and environmental
factors involved in the appearance and progression of this
condition [6,7].
The genetic predisposition to develop uveitis has long been
investigated. The association between certain HLA alleles,
particularly HLA-A29 in birdshot chorioretinopathy and HLA-
B27 in anterior uveitis, is well known [8,9]. However, HLA
accounts for only a small part of the genetic predisposition to
immune-mediated uveitis.
Outside the HLA region, several genes have been proposed
to play a role in the development of diseases involving uveitis;
however only a few loci have been confirmed as genetic risk
factors, such as IL23R/IL12RB2 or IL10 in Behçet’s disease
(BD) [10,11], and, currently, the overall underlying mechanisms
of the uveitis induction remain unclear.
The type I interferons (IFNs) are signalling molecules
involved in both innate and adaptive immunity. The IFN
pathway has been postulated to play a crucial role in
autoimmune diseases. Specifically, several single nucleotide
polymorphisms (SNPs) on the interferon regulatory factor 5
(IRF5) gene, a major regulator of the type I IFN induction and
critical for the production of pro-inflammatory cytokines, have
been associated with different autoimmune conditions such as
rheumatoid arthritis, systemic lupus erythematosus (SLE),
multiple sclerosis, systemic sclerosis, inflammatory bowel
disease and Sjöegren’s syndrome [12–17]. In SLE, three
independent sets of correlated IRF5 variants that provide
statistically independent evidence for association have been
reported [18]. Polymorphisms in each of these groups seem to
have different functional consequences such as alteration of a
consensus splice donor site allowing expression of an
alternative exon 1, creation of an early polyadenylation site that
leads to a shorter isoform and alteration of the protein stability.
It has been suggested that autoimmune uveitis shares
different genetic factors with other autoimmune disorders [19].
The aim of our study was to analyze three SNPs,
representative of each group of variants independently
associated with SLE, in order to explore the role of IRF5 in
uveitis susceptibility and its clinical subgroups.
Patients and Methods
Ethics statement
A subject’s written consent was obtained according to the
declaration of Helsinki, and the design of the work was
approved by the Ethics Committee of Granada (Spain). The
Ethics Committees of the Hospital de León (León), Hospital
Universitario Príncipe de Asturias (Alcalá de Henares), Hospital
de Cruces (Bilbao), Hospital Clinic (Barcelona), Hospital
Clínico San Carlos (Madrid), Hospital Marqués de Valdecilla
(Santander), Hospital Universitario La Fe (Valencia), Hospital
Clínico San Cecilio (Granada) and Hospital Carlos Haya
(Málaga) also approved the study.
Patients
A total of 263 patients with non-infectious uveitis, excluding
the exclusively anterior uveitis forms as well as uveitis
associated with systemic immune-mediated diseases except
Vogt-Koyanagi-Harada syndrome, and 724 ethnically matched
healthy controls, all of them from Spain, were included in the
present study.
In addition, to examine whether the selected SNPs might
influence the different clinical manifestations of the disease,
uveitis patients were subdivided according to different
characteristics included in Table 1. The intraocular
inflammation seen in patients included intermediate uveitis
(24.0%), posterior uveitis (51.7%), and panuveitis (24.3%).
Macular edema was diagnosed by biomicroscopy and optical
coherence tomography (Cirrus HD-OCT, Carl Zeiss Meditec,
Inc). Scans were obtained using the 512 x 128 scan pattern.
Fluorescein angiography (FA) was performed to rule out
macular edema in doubtful cases. Macular edema was defined
as a macular thickness greater than 250 µm with the presence
of intraretinal cysts demonstrated by OCT [20], and/or the
presence of retinal angiographic leakage in the central macula
area for those patients in which FA was performed.
Genotyping
Genomic DNA was extracted from peripheral white blood
cells and saliva, using standard procedures. Three SNPs,
rs2004640, rs2070197 and rs10954213, located on the IRF5
gene, were genotyped using a pre-designed TaqMan® allelic
discrimination assay in a 7900HT Real-Time polymerase chain
reaction (PCR) System from Applied Biosystems (Foster City,
CA, USA). The genotype call rate was 99% for the tested
genetic variants. In addition, randomly selected samples were
genotyped twice to verify the genotyping accuracy. The 99% of
the genotypes were identical.
Statistical analysis
We carried out a case-control study using Plink (v1.07)
(http://pngu.mgh.harvard.edu/purcell/plink/). The genotype,
allele and carrier frequencies were compared between
patients, subgroup of patients and controls applying χ2 test
Table 1. Clinical and demographic features of uveitis
patients.
General characteristics of uveitis patients Uveitis (n=263) Controls (n=724)
Female (%) 146 (55.5) 481 (66.4)
Age (mean ± SD) 48.3 ± 16.4 49.1 ± 12.5
Intermediate Uveitis (%) 63 (24.0) -
Posterior Uveitis (%) 136 (51.7) -
Panuveitis (%) 64 (24.3) -
Bilaterality (%) 206 (78.3) -
Vitritis (%) 177 (67.3) -
Macular edema (%) 121 (46.0) -
Retinal vasculitis (%) 116 (44.1) -
Choroidal neovascularization (%) 25 (9.51) -
doi: 10.1371/journal.pone.0076777.t001
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and/or Fisher’s exact test when necessary (when the expected
frequencies were lower than 5). Odds ratios (OR) and 95%
confidence intervals (CI) were obtained according to Woolf’s
method. Since different polymorphisms were analyzed in the
current study, the Benjamini & Hochberg (1995) step-up false
discovery rate (FDR) control correction for multiple testing was
applied to the P-values. P-values after FDR correction lower
than 0.05 were considered as statistically significant.
Dependency of association between the studied genetic
variants was determined by conditional logistic regression
analysis implemented in PLINK, and the allelic combinations
were tested using PLINK and Haploview (V. 4.2).
To analyze whether allelic combinations would better explain
the possible association than the genetic variants
independently, we compared the goodness of fit of both models
using PLINK. For that purpose, we calculated the deviance
(defined as -2 x the log likelihood), which follows a χ2
distribution, to assess the significance of the improvement in fit.
If statistically significant differences in the improvement of fit
were observed when the haplotype effect was considered, we
assumed that this model was more informative explaining the
putative association.
Results
No statistically significant deviation from Hardy-Weinberg
equilibrium (P> 0.01) was observed for every SNP in the
controls set and the frequencies of the analyzed SNPs were in
agreement with the data of the HapMap project.
Allele test
As shown in Table 2, when genotype and allelic frequencies
were compared between uveitis patients and controls, a trend
of association of rs2004640 and rs10954213 with uveitis was
found. However, the stratification of uveitis patients accordingly
with the presence/absence of the different clinical
characteristics, showed in Table 1, evidenced that these
signals were due to a specific association with patients without
macular edema (rs2004640: PFDR=5.07E-03, OR=1.48, CI
95%=1.14-1.92; rs10954213: PFDR=3.37E-03, OR=1.54, CI
95%=1.19-2.01). Consistently, statistically significant
differences were observed when comparing uveitis patients
with and without this trait (rs2004640: P=0.037, OR=0.69, CI
95%=0.48-0.98; rs10954213: P=0.030, OR=0.67, CI
95%=0.47-0.96) (Table 2).
Conditional logistic regression
Since an independent effect of the two associated SNPs has
been reported, we decided to perform pairwise conditioning
analysis to test whether there could be any dependence among
them (Table S1). However, both SNPs lost the statistical
significance after conditioning to each other.
Haplotype analysis
We also carried out the allelic combination analysis for
studied IRF5 polymorphisms (Figure S1 shows the linkage
disequilibrium between the three analyzed polymorphisms).
This analysis also showed a phenotype-specific association of
IRF5 with the absence of macular edema (Table 3) but not with
the global disease (data not shown). Two associated
haplotypes, containing the risk and protective alleles of the two
associated SNPs, were found in the comparison between
patients without macular edema and controls (rs2004640*G-
rs2070197*T-rs10954213*G: PFDR=0.011, OR=1.51, CI
95%=1.16-1.98; rs2004640*T-rs2070197*T-rs10954213*A:
PFDR=0.020, OR=0.70, CI 95%=0.53-0.92). When patients with
and without edema were compared, an association of the
rs2004640*G-rs2070197*T-rs10954213*G haplotype was also
evident (P=6.69E-03, OR=0.59, CI 95%=0.41-0.86).
Table 2. Genotype and minor allele frequencies of IRF5 genetic variants in uveitis patients and healthy controls.
   Genotype, N (%)  Allele test
SNP 1/2 Subgroup (N) 1/1 1/2 2/2 MAF (%) P-value* PFDR** OR [CI 95%]***
rs2004640 a G/T Controls (n=723) 135 (18.67) 356 (49.24) 232 (32.09) 43.29    
  Uveitis (n=258) 58 (22.48) 132 (51.16) 68 (26.36) 48.06 0.0613 0.0919 1.21 [0.99-1.48]
  With edema (n=119) 25 (21.01) 54 (45.38) 40 (33.61) 43.70 0.9068 0.9068 1.02 [0.77-1.34]
  Without edema (n=134) 32 (23.88) 78 (58.21) 24 (17.91) 52.99 3.38E-03 5.07E-03 1.48 [1.14-1.92]
rs2070197 b C/T Controls (n=723) 9 (1.24) 113 (15.63) 601 (83.13) 9.06    
  Uveitis (n=261) 1 (0.38) 35 (13.41) 225 (86.21) 7.09 0.1671 0.1671 0.77 [0.52-1.12]
  With edema (n=120) 0 (0.00) 17 (14.17) 103 (85.83) 7.08 0.3164 0.9068 0.77 [0.45-1.29]
  Without edema (n=136) 1 (0.74) 17 (12.50) 118 (86.76) 6.99 0.2662 0.2662 0.75 [0.46-1.24]
rs10954213 c G/A Controls (n=723) 88 (12.17) 323 (44.67) 312 (43.15) 34.51    
  Uveitis (n=261) 48 (18.39) 112 (42.91) 101 (38.70) 39.85 0.0293 0.0880 1.26 [1.02-1.55]
  With edema (n=120) 19 (15.83) 47 (39.17) 54 (45.00) 35.42 0.7843 0.9068 1.04 [0.78-1.39]
  Without edema (n=136) 29 (21.32) 64 (47.06) 43 (31.62) 44.85 1.12E-03 3.37E-03 1.54 [1.19-2.01]
* All P-values have been calculated for the allelic model. ** Benjamini & Hochberg (1995) step-up FDR control. *** Odds ratio for the minor allele.
a Uveitis with edema vs. uveitis without edema: P= 0.037, OR (CI 95%)=0.69 (0.48-0.98); b Uveitis with edema vs. uveitis without edema: P=0.966, OR (CI 95%)=1.02
(0.52-2.00); c Uveitis with edema vs. uveitis without edema: P = 0.030, OR (CI 95%)=0.67 (0.47-0.96);
doi: 10.1371/journal.pone.0076777.t002
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When comparing the haplotype model with the independent
SNP model, we did not observe a statistically significant
improvement of the goodness of fit compared to rs2004640
(without macular edema vs. controls: likelihood P-value=0.073;
with vs. without macular edema: likelihood P-value=0.071) or
rs10954213 (without macular edema vs. controls: likelihood P-
value=0.180; with vs. without macular edema: likelihood P-
value=0.061) individually.
Discussion
IRF5 is member of a family of transcription factors that play a
crucial role in the control of inflammatory and immune
responses. Several studies have established that IRF5 is
involved in the production of type I IFNs and it is critical for the
production of the pro-inflammatory cytokines TNF-α, IL-12 and
IL-6, following Toll-like receptor signaling [21]. Recently the role
of the type I interferon pathway in the development of
autoimmunity has become increasingly important. Additionally,
several genetic studies have identified IRF5 genetics variants
associated with an increased risk of several autoimmune
diseases [12–17].
Three groups of correlated IRF5 SNPs, designated as
Groups 1, 2 and 3, independently associated with SLE and with
different functional roles have been described [18]. Group 1
includes SNPs tagging a 30-bp in-frame INDEL variant of exon
6 that alters protein stability; the association of the Group 2
SNPs seems to be explained by the T allele of rs2004640
which allows the expression of an alternative isoform 1B and is
associated with significantly higher levels of IRF5 expression;
and finally, the association of the Group 3 SNPs is probably
due to the rs10954213 A allele that creates an early
polyadenylation site leading to a higher IRF5 expression
[18,22,23]. All the risk alleles of these polymorphisms
segregate in a strongly associated haplotype tagged by the C
allele of the rs2070197, belonging to Group 1.
In the present study we analyzed one tagging SNP of each
group of independent signals, rs2004640, rs2070197 and
rs10954213. No association of any of these polymorphisms
with the global disease was evident, however, our results
clearly showed that two of the three analyzed variants,
rs2004640 and rs10954213, influence the development of
macular edema in uveitis patients, supported by a high
statistical power; as shown in Table S2, the statistical power of
our study is higher than 80% to detect the observed odds ratio
(OR=1.5). It was not possible to determine whether these two
genetic variants represent independent signals in uveitis, as
previously reported in other autoimmune diseases. The fact
that the conditional logistic regression analysis showed no
conclusive results could be due to a reduced statistical power.
On the other hand, no additive effect among these two
functional IRF5 polymorphisms was evident, since the model
considering a haplotype effect did not better explain the
observed association than that of the independent SNPs.
Nevertheless, this should be taken with caution, because a lack
of statistical power could also represent a limitation in this
analysis; indeed, the comparison of the goodness of fit of both
models almost reached statistical significance. Regarding
rs2070197, we found no evidence of association with non-
anterior uveitis or clinical subphenotypes. However, the
statistical power of this analysis was compromised due to the
low frequency of the minor allele and, therefore, weak effects
were hardly detected.
Opposed to our results, a previous study performed in Han
Chinese population [24] failed to show association between two
IRF5 polymorphisms, rs2280714 and rs752637, and BD. It is
important to note that both belong to Group 3 and are highly
correlated with rs10954213 (r2>0.8); therefore, these genetic
variants have been covered in our study.
In uveitis, macular edema forms a major cause of visual
impairment and blindness [2]. The exact pathogenesis of this
trait in patients with uveitis is not clear but the cause of
pathologic fluid retention and protein accumulation within the
retina seems to be a disruption of the blood retinal barrier
(BRB) formed by the zonulae occludentes and adhaerentes of
the retinal pigment epithelial cells (outer barrier) and
endothelial cells of retinal vessels (inner barrier). Intraocular
inflammation may lead to the disturbance of the BRB via the
release of local inflammatory mediators. It has been shown that
IL-6 may indirectly cause an increase of vascular permeability
and angiogenesis by inducing the expression of VEGF
(vascular endothelial growth factor), a major known factor in
angiogenesis and vasopermeability in the eye [25]. Elevated
Table 3. Different allelic combinations of the IRF5 genomic region according to the presence/absence of macular edema in
uveitis patients.
    Without macular edema vs. controls With vs. Without macular edema
Allelic combination Freq. With edema Freq. Without edema Freq. Controls P-value PFDR OR [95% CI] P-value PFDR* OR [95% CI]
GTG 0.279 0.397 0.304 2.22E-03 0.011 1.51 [1.16-1.98] 6.69E-03 0.033 0.59 [0.41-0.86]
TTA 0.413 0.349 0.435 8.06E-03 0.020 0.70 [0.53-0.92] 0.108 0.271 1.31 [0.91-1.87]
GTA 0.163 0.132 0.129 0.887 0.351 1.05 [0.71-1.53] 0.451 0.375 1.27 [0.78-2.07]
TCA 0.071 0.070 0.091 0.281 0.351 1.00 [0.83-1.20] 0.939 0.375 1.00 [0.78-1.28]
TTG 0.075 0.051 0.041 0.491 0.491 1.32 [0.73-2.37] 0.375 0.375 1.47 [0.72-2.99]
Order of the SNPs: rs2004640*G/T │rs2070197*C/T │rs10954213*A/G
*. Benjamini & Hochberg (1995) step-up FDR control
OR, odds ratio
doi: 10.1371/journal.pone.0076777.t003
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levels of intraocular IL-6 and TNF-α, whose expression is
upregulated by IRF5, have been reported in patients with
intermediate uveitis, especially in those with macular edema
[26].
Our data are consistent with these findings. Taking into
account that the frequency of the rs2004640*T and
rs10954213*A alleles is lower in the group of patients without
macular edema than in those presenting this trait, it could be
speculated that patients without edema present decreased
IRF5 levels and, therefore, lower levels of inflammatory
cytokines involved in the development of macular edema,
including TNF- α and IL-6.
Interestingly, several studies have reported that the
treatment with type I IFNs (IFN-β-1 and IFN-α-2a) leads to
complete or partial resorption of macular edema in a high
percentage of uveitis patients [27,28], thus supporting the key
role of the IFN signaling in this trait.
In conclusion, we show for a first time that two genetic
variants within the IRF5 region influence the macular edema
development in patients with non-anterior uveitis. Functional
studies will be necessary to clarify the implication of the IRF5
alleles in the pathophysiology of this trait.
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